About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
Ginkgo Bioworks image

Ginkgo Bioworks

Rank#7741
Market Cap470.71M
CountryUnited States
Summary
History
Mission
Vision
References
Summaryarrow
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Historyarrow

On 16 December 2020, it was reported that Ginkgo Bioworks would acquire the primary assets of Novogy's Microbial Engineering Platform. On 11 May 2021, Gingko Bioworks announced plans of going public through a merger with SPAC Soaring Eagle at a $17.5 billion valuation.On 14 May 2021, Ginkgo announced its new ticker for the NYSE will be DNA. The ticker was previously used by Genentech, who stopped using the ticker after they were acquired by Roche. Trading began on September 17, 2021. The investment management firm Baillie Gifford became the largest shareholder with the purchase of 167.75 million shares on 31 March 2022.On 14 March 2022, it was reported that Ginkgo Bioworks signed a Definitive Agreement to Acquire FGen AG, a leading bioengineering company and its proprietary ultra-high-throughput screening platform. On 6 June 2022, it was reported that Ginkgo Bioworks has acquired assets from Bitome, an Integrated Metabolite Monitoring Platform. On 25 July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million in an all-stock deal.On 27 July 2022, it was reported that Ginkgo Bioworks would acquire Bayer's Biologics Research & Development site, located in West Sacramento. Ginko will enter into a new multi-year platform collaboration with Bayer. The deal includes the integration of the R&D platform assets from Joyn Bio, a joint-venture between Leaps by Bayer investments and Ginkgo Bioworks. On 4 October 2022, it was reported that Ginkgo Bioworks would acquire France-based adaptive laboratory evolution instruments developer Altar and California-based Circularis to strengthen capabilities in cell and gene therapy.In October 2022, Bloomberg News reported that Ginkgo Bioworks partnered with Intelligence Advanced Research Projects Activity to create a software tool to help detect when biological organisms have been genetically engineered. The tool known as ENDAR could be used to provide an early warning of bioweapons and other man-made biological threats.

Missionarrow
Our mission is to make biology easier to engineer. We are building an organism design automation platform to enable our partners to quickly develop microbial strains for use in production and start-up applications.
Visionarrow
Our vision is to use biology as a technology platform to enable a sustainable future. We are focused on creating and delivering biobased products that can work in harmony with nature to meet the global needs of people and the planet.
Referencesarrow

https://en.wikipedia.org/wiki/Ginkgo_Bioworks

https://in.investing.com/equities/soaring-eagle-acquisition

https://finance.yahoo.com/quote/DNA/profile?p=DNA

https://www.crunchbase.com/organization/ginkgo-bioworks

https://sec.report/CIK/0001830214

https://companiesmarketcap.com/

https://www.ginkgobioworks.com

Share

Leadership team
D
Dr. Jason Kelly (Founder, CEO & Director)
D
Dr. Reshma P. Shetty (Founder, Pres, COO & Director)
M
Mr. Mark E. Dmytruk (Chief Financial Officer)
Products / Services
Biopharma, Biotechnology, Chemical
Number of Employees
500 - 1000
Address
Boston, Massachusetts, United States
Established
2008-01-01
Company Registration
SEC CIK number: 0001830214
Revenue
500M - 1B
Traded as
DNA
Website
https://www.ginkgobioworks.com
Social Media
linkedinfacebookx
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Email
Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo